Company news
Revolution Medicines, Inc. news in 2020
Revolution Medicines, Inc.'s news releases, calls and decks from 2020, newest first.
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
November 11, 2020
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 23, 2020
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
October 11, 2020
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
September 15, 2020
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 8, 2020
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
September 7, 2020
Decks in 2020
- Investor Presentation (June 2020)
Investor deck · 40 slides · Jun 22, 2020